SIGACHISigachi Industries Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company offers cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab names; and various chemicals, including colloidal silicon dioxide, carboxy cellulose sodium and mannitol, etc. to active pharmaceutical ingredients, food and nutrition, cosmetic, and chemical industries. It also provides operations and maintenance services in the fields of speciality chemicals, petrochemicals, water treatment, and pharmaceuticals. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SIGACHI — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Debt/Equity: 0.31
- • MACD: bullish
- • Price vs EMA21: above
- • Price vs SMA50: above
- • 1-month return: +36.6%
- • 1-month vs NIFTY: +40.7% relative
Bull case
- • Debt/Equity: 0.31
- • MACD: bullish
- • Price vs EMA21: above
- • Price vs SMA50: above
Bear case
- • Revenue growth: -4.7% YoY
- • Profit growth: -217.5% YoY
- • Volume: 0.9x 20-day average
- • Volatility: 56% annualized
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -4.7% YoY
- • Profit growth: -217.5% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹1.86). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.